Recall Of Blood Pressure Drug Losartan Expanded
(CNN) — If you take blood pressure medicine, you’ll want to double-check your bottle. Torrent Pharmaceuticals Ltd. has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets. Tests found trace amounts of a potentially cancer-causing impurity called N-methylnitrosobutyric acid in some of these drugs. The company is recalling 36 additional lots, it said Thursday. A full list of recalled drugs is available on the US Food and Drug Administration website. Some of the recalled blood pressure medication (Image credit: FDA) The company hasn’t had any reports of users getting ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News losartan Source Type: news

FDA urges patients to keep taking contaminated blood pressure drugs
Many valsartan-containing drugs have been recalled for a carcinogen. Amid shortages of untainted drugs, the FDA says not taking them poses a greater risk than the low levels of carcinogen does. (Source: the Mail online | Health)
Source: the Mail online | Health - April 5, 2019 Category: Consumer Health News Source Type: news

Blood pressure patients can take tainted pills during valsartan shortage, FDA says
Due to a shortage of certain commonly used blood pressure drugs, the US Food and Drug Administration took the unusual step Thursday of reminding patients that they have access to available -- if tainted -- medicines while a fresh supply of uncontaminated pills is manufactured. (Source: CNN.com - Health)
Source: CNN.com - Health - April 4, 2019 Category: Consumer Health News Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the agency ’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue
FDA announces list of nitrosamine-free ARB medications confirmed by the agency to help patients and healthcare providers (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 4, 2019 Category: American Health Source Type: news

PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains
Failure to start therapy in hospital is a'lost opportunity,'say researchers from evidence that such early sacubitril/valsartan bested enalapril more in the earliest weeks after discharge than later.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

amlodipine and valsartan (Exforge)
Title: amlodipine and valsartan (Exforge)Category: MedicationsCreated: 7/27/2010 12:00:00 AMLast Editorial Review: 3/19/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 19, 2019 Category: Cardiology Source Type: news

Cheap blood pressure drugs could increase survival chances for men with prostate cancer 
Scientists at the Universtiy of Tampere in Finland led the study. They found the class of blood pressure drug called angiotensin II receptor blockers had the benefit. They include pills such as valsartan. (Source: the Mail online | Health)
Source: the Mail online | Health - March 19, 2019 Category: Consumer Health News Source Type: news

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. (Source: World Pharma News)
Source: World Pharma News - March 15, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

FDA combats valsartan shortage with new generic approval
As recalls widen for the popular blood pressure medication, valsartan, the FDA has approved a new generic version of the drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 14, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves New Generic Valsartan to Ease Shortage
WEDNESDAY, March 13, 2019 -- The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage. The agency said it... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2019 Category: Pharmaceuticals Source Type: news

After multiple recalls, FDA OK's new generic for valsartan
FDA said new approval will help alleviate shortages of blood pressure drugs after repeated recalls over cancer-causing chemicals (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 13, 2019 Category: Consumer Health News Source Type: news

FDA OKs a New Generic of the Blood Pressure Drug Valsartan to Ease Shortage Due to Recalls
WEDNESDAY, March 13, 2019 -- The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage. The agency said... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 13, 2019 Category: General Medicine Source Type: news

FDA Fast-Tracks Approval of Generic Valsartan FDA Fast-Tracks Approval of Generic Valsartan
Amid ongoing tainted sartan drug recalls, the US Food and Drug Administration has approved a new generic of valsartan (Diovan) to treat hypertension and heart failure.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 13, 2019 Category: Neurology Tags: Cardiology News Alert Source Type: news

FDA Allows For a New Generic Valsartan
(MedPage Today) -- Approval comes in response to ARB shortage (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 12, 2019 Category: Pediatrics Source Type: news

FDA Allows New Generic Valsartan
(MedPage Today) -- Approval comes in response to ARB shortage (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 12, 2019 Category: Pediatrics Source Type: news

FDA approves a new generic valsartan
Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine (Source: World Pharma News)
Source: World Pharma News - March 12, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA approves new generic valsartan to make up for drug shortage
The US Food and Drug Administration approved a new generic of valsartan on Tuesday to help relieve the recent shortage of the medicine, which is used to treat high blood pressure. (Source: CNN.com - Health)
Source: CNN.com - Health - March 12, 2019 Category: Consumer Health News Source Type: news

FDA approves generic valsartan amid drug shortage
The U.S. Food and Drug Administration said on Tuesday it had approved a new generic version of blood pressure medicine valsartan, as the agency looks to ease shortages triggered by several manufacturers recalling the drug over possible cancer risk. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves a New Generic Diovan (valsartan)
March 12, 2019 -- Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 12, 2019 Category: Pharmaceuticals Source Type: news

FDA approves a new generic valsartan
FDA has approved a new generic of Diovan (valsartan). The agency prioritized the review of this drug application to help relieve a recent shortage of the drug. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 12, 2019 Category: American Health Source Type: news

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
American Health Packaging is voluntarily recalling one lot of Valsartan Tablets, USP, 160 mg to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-Nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. This recall is being initiated in response to the recall by the manufacturer (Aurobi...
Source: Food and Drug Administration - March 7, 2019 Category: Food Science Source Type: news

Blood Pressure Medication Recall Expands Again To Include Losartan
(CNN) — A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan. The recall is due to an “impurity” that is classified as a potential human carcinogen. The impurity, N-Nitroso-N-methyl-4-aminobutyric acid or NMBA, is also classified as a known animal carcinogen, the US Food And Drug Administration noted in a news release about the recall Friday. Camber Pharmaceuticals Inc. voluntarily recalled 87 lots of losartan tablets in the United States on Thursday. The recalled tablets, made by Hetero Labs Ltd. In India and distributed by...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News FDA losartan Valsartan Source Type: news

AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity.
AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) cl...
Source: Food and Drug Administration - March 1, 2019 Category: Food Science Source Type: news

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Go ahead for first add-on tablet to insulin treatment for type 1 diabetes
European regulator recommends dapagliflozin for those with poor blood glucose control despite best efforts Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD Adding insulin to metformin linked to higher mortality Draft diabetes guidance too heavily focused on cost, protests industry MHRA tightens licence restrictions on valproate for women Withdrawn valsartan meds not linked to short-term cancer risk (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 5, 2019 Category: UK Health Source Type: news

Morning Break: Generic Advair; Polar Vortex Deaths; Valsartan Gouging
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - January 31, 2019 Category: Pediatrics Source Type: news

Cancer Fears Have Triggered Blood Pressure Drug Recalls for Months. Now Patients Are ‘Leery’
Cynthia Brown had been taking the drug valsartan for about two years when she learned last August that it had been recalled over fears of potential carcinogen contamination. Brown, a writer and patient advocate living near Cincinnati, had been prescribed valsartan to control shortness of breath related to primary pulmonary hypertension, but suddenly she had a whole new concern: cancer. “I’ve always been very conscientious about my health. I never dreamed I’d be on all these medications, and I’m real funny about what I take,” Brown, 65, says. “Valsartan has made me leery of all medication...
Source: TIME: Health - January 29, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime Source Type: news

FDA warns of blood pressure med shortage
FDA Commissioner Scott Gottlieb and CDER Director Janet Woodcock released a statement warning of a shortage of ARBs, or angiotensin II receptor blockers, which contain valsartan. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 28, 2019 Category: Pharmaceuticals Source Type: news

FDA warns of common blood pressure medicine shortage due to recalls
The US Food and Drug Administration is warning of a shortage of a class of drugs used by millions to treat high blood pressure. The drugs known as ARBs, or angiotensin II receptor blockers, contain valsartan. (Source: CNN.com - Health)
Source: CNN.com - Health - January 27, 2019 Category: Consumer Health News Source Type: news

2 MILLION people have been exposed to cancer-causing chemicals in contaminated blood pressure drugs
Last summer, it emerged widely-prescribed drugs for heart failure and hypertension - including  valsartan and irbesartan - had dangerously high levels of recognized carcinogens. (Source: the Mail online | Health)
Source: the Mail online | Health - January 26, 2019 Category: Consumer Health News Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the FDA ’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues
FDA describes the ongoing investigation into the ARB class impurities and agency ’s steps to address the root causes of the safety issues (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 25, 2019 Category: American Health Source Type: news

Some irbesartan medicines recalled
MHRA recall some blood pressure and heart medication because of contamination fears Related items fromOnMedica Blood pressure measurement Hypertension: what ’s new and how might this impact practice? Withdrawn valsartan meds not linked to short-term cancer risk Exercise may be as good at lowering blood pressure as drugs Treatment of hypertension for low-risk patients questioned (Source: OnMedica Latest News)
Source: OnMedica Latest News - January 7, 2019 Category: UK Health Source Type: news

Heart Drug Recall Expanded Again
(CNN) — The recall of popular heart drugs has expanded yet again. The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes. This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Recall Valsartan Source Type: news

Heart drug recall expanded again
The recall of heart drugs has expanded again to include Torrent Pharmaceuticals losartan potassium and Aurobindo Pharma USA Inc. drugs containing valsartan. (Source: CNN.com - Health)
Source: CNN.com - Health - January 4, 2019 Category: Consumer Health News Source Type: news

More Tainted Valsartan Products Recalled More Tainted Valsartan Products Recalled
Aurobindo Pharma USA has recalled 80 lots of medicines containing valsartan, owing to the presence of the probable carcinogen N-nitrosodiethylamine (NDEA).News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Another batch of blood pressure drugs recalled over traces of cancer-causing chemical  
Last summer, it emerged valsartan produced in China was contaminated with a carcinogen called NDEA, prompting a global recall. Now, the same has happened with an Indian manufacturer. (Source: the Mail online | Health)
Source: the Mail online | Health - January 3, 2019 Category: Consumer Health News Source Type: news

FDA expands recall on blood pressure drug valsartan due to probable carcinogen
The FDA is expanding a recall of a popular blood pressure drug over concern it may contain an unwanted ingredient that can cause cancer. Aurobindo Pharma says it is voluntarily recalling tablets with the ingredient valsartan because it found trace amounts of a substance known as NDEA. Recalls of contaminated valsartan products started in July and involve seven different companies. Dr. Tara Narula joins "CBS This Morning" with more on the latest recall. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 3, 2019 Category: Consumer Health News Source Type: news

FDA issues new recall for blood pressure meds containing valsartan
A voluntary recall has been issued for a blood pressure medication due to concerns it contains small amounts of carcinogens called N-nitrosodiethylamine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 2, 2019 Category: Consumer Health News Source Type: news

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.
A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US
A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. To date, Aurobi...
Source: Food and Drug Administration - January 1, 2019 Category: Food Science Source Type: news

Valsartan Recall Expanded, FDA Investigating Products From Outside China
(MedPage Today) -- Other ARB manufacturers subject to FDA investigation (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 23, 2018 Category: American Health Source Type: news

Do Neprilysin Inhibitors Have a Role in Patients With CKD? Do Neprilysin Inhibitors Have a Role in Patients With CKD?
Dr Desai reviews the UK HARP-III trial, which compares the effects of sacubitril/valsartan and irbesartan on kidney function in people with CKD.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2018 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

FDA Warns Manufacturer Involved in Valsartan Recall FDA Warns Manufacturer Involved in Valsartan Recall
FDA has notified Zhejiang Huahai Pharmaceuticals it is subject to an ongoing investigation and outlines'serious'manufacturing violations.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications
FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 11, 2018 Category: American Health Source Type: news

WATCH: Recall involving blood pressure medications expanding
Drugmaker Mylan is recalling 104 lots of three medications that include Valsartan after testing found trace amounts of a carcinogen. (Source: ABC News: Health)
Source: ABC News: Health - December 8, 2018 Category: Consumer Health News Tags: WNT Source Type: news

Valsartan Blood Pressure Drug Recall Widens
The drugs were recalled because of trace amounts of an impurity, N-nitrosodiethylamine, or NDEA, which may cause cancer in humans, according to the International Agency for Research on Cancer. (Source: WebMD Health)
Source: WebMD Health - December 7, 2018 Category: Consumer Health News Source Type: news

More Blood Pressure Meds Recalled Due to Carcinogen
FRIDAY, Dec. 7, 2018 -- Over the past few months, numerous recalls of the popular heart drug valsartan have already occurred. Now, generics maker Mylan Pharmaceuticals is adding more products to the list. The recall involves 104 lots of three... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2018 Category: General Medicine Source Type: news

Mylan Expands Recall to All Unexpired Lots of Valsartan in US Mylan Expands Recall to All Unexpired Lots of Valsartan in US
The latest recall stems from NDEA contamination and includes 26 lots of amlodipine/valsartan tablets, 51 lots of valsartan tablets, and 27 lots of valsartan/hydrochlorothiazide tablets.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths). (Source: Food a...
Source: Food and Drug Administration - December 4, 2018 Category: Food Science Source Type: news